In vivo intensification of free-radical oxidation of low-density lipoproteins in the plasma of patients with coronary heart disease treated with β-hydroxy-β-methylglutaryl coenzyme A reductase inhibitor pravastatin and inhibition of lipid peroxidation with ubiquinone Q10
Authors:
- 1 February 2000
- journal article
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 129 (2) , 151-154
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Effect of Pravastatin on Angiographic Restenosis After Coronary Balloon Angioplasty fn1fn1This study was supported by a grant from Bristol Myers Squibb Laboratories, Paris.JACC, 1997
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Apolipoprotein B-Bound Lipids as a Marker for Evaluation of Low Density Lipoprotein Oxidation in VivoBiochemical and Biophysical Research Communications, 1995
- Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans*Clinical Pharmacology & Therapeutics, 1995
- The oxidation hypothesis of atherosclerosisThe Lancet, 1994
- Measurement of Plasma Hydroperoxide Concentrations by the Ferrous Oxidation-Xylenol Orange Assay in Conjunction with TriphenylphosphineAnalytical Biochemistry, 1994
- Cholesterol reduction in the prevention of coronary heart disease: therapeutic rationale and guidelinesHeart, 1993
- Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does alpha-tocopherol.Proceedings of the National Academy of Sciences, 1991
- Lovastatin decreases coenzyme Q levels in humans.Proceedings of the National Academy of Sciences of the United States of America, 1990